ArticleClinical, cosmetic and investigational dermatology2026
Global Burden and Demographic Decomposition of Seborrheic Dermatitis, 1990-2023: A Secondary Analysis of GBD 2023 Estimates.
Article in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Case counts of seborrheic dermatitis have progressively increased, which may reflect population growth, changing age structure, and changing age-specific rates. We quantified these components within a consistent Global Burden of Disease (GBD) 2023 series. Methods: We analyzed incidence, prevalence, and disability-adjusted life-years (DALYs) for 1990-2023 globally and by region, sex, age, and Socio-demographic Index group. Symmetric Das Gupta decomposition partitioned changes in global counts into population-size, age-structure, and age-specific-rate components. Replacement-order and age-group sensitivities assessed component directions. Deterministic scenarios combined fixed 2023 age-specific rates with each UN World Population Prospects 2024 variant's age-specific populations through 2040. Results: In 2023, modeled incident cases totaled 183.94 million (95% uncertainty interval 170.17-197.03 million), prevalent cases 26.73 million (25.14-28.48 million), and DALYs 358,629 (206,994-558,580), increasing by 50.7%, 62.3%, and 61.3% from 1990. Age-standardized rates changed by 0.31%, 0.23%, and 0.38%, respectively. Population growth accounted for 100.8%, 85.1%, and 86.2% of the net increases. Age-structure change contributed -1.7% to incident cases but +14.2% to prevalent cases and +12.8% to DALYs; age-specific-rate changes contributed 0.9%, 0.6%, and 1.0%. Age-structure component directions persisted across replacement orders and ten-year age grouping. The fixed-rate Medium scenario yielded 204.18 million incident cases in 2040. Conclusion: Within GBD 2023 point estimates, population growth was the main accounting component of increasing absolute burden. Age-structure change contributed in opposite directions to incidence versus prevalence and DALYs. These descriptive results support reporting counts alongside standardized rates; they do not establish individual disease duration or biological mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.